Validation of a Wireless Wearable Vital Signs Monitor in Pediatric Patient
28 juli 2026 uppdaterad av: Guilherme Sant'Anna, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre
Wireless Skin-Adherent Physiologic Sensor Validation in Pediatric Patients - Phase 1 Clinical Study
This prospective observational study aims to evaluate the accuracy, safety, and feasibility of the ANNE® Chest wireless wearable sensor for continuous monitoring of heart rate, respiratory rate, oxygen saturation, and skin temperature in hospitalized neonates, infants, and children (0 days to 12 years of age) in the neonatal and pediatric intensive care units (NICU and PICU).
Measurements obtained from the wireless device will be compared with standard-of-care bedside monitoring and capnography.
The study will also assess skin tolerability, signal reliability, and caregiver and healthcare provider perceptions of the device.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Observationell
Inskrivning (Beräknad)
42
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Alyssa Maximov, BSc.
- Telefonnummer: 78229 5149341934
- E-post: alyssa.maximov@muhc.mcgill.ca
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
Tar emot friska volontärer
Nej
Testmetod
Icke-sannolikhetsprov
Studera befolkning
Hospitalized neonates, infants, and children (0 days to <12 years of age) admitted to the NICU or PICU at the Montreal Children's Hospital who require continuous physiologic monitoring and whose parent or legal guardian provides informed consent.
Beskrivning
Inclusion Criteria:
- Neonates (0-28 days of life)
- Infants (29 days of life - 2 years, i.e., not turned 2 years old)
- Children (2 years old - 12 years old, i.e., not turned 12 years old)
Exclusion Criteria:
- Contraindication to application of skin sensors (e.g., rash, surgical site, skin breakdown, open wounds, burns, active dermatitis, etc.) at the application site.
- Severe hemodynamic instability requiring escalating interventions.
- Congenital airway abnormalities interfere with accurate capnography.
- Diagnosed neuromuscular disorders affecting respiratory mechanics.
- Known adhesive allergies.
- Inability to tolerate device placement due to behavioral issues.
- Participation in conflicting clinical trials.
- High-frequency oscillatory or mechanical ventilation.
- Active bronchiolitis with mask intolerance.
- Recent facial surgery preventing EtCO₂ nasal line placement.
- Behavioral conditions preventing adherence to device wearing.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Neonates
Hospitalized neonates aged 0-28 days admitted to the neonatal intensive care unit (NICU) or pediatric intensive care unit (PICU).
|
Participants will wear the ANNE® Chest wireless skin-adherent physiologic sensor for continuous monitoring of heart rate, respiratory rate, electrocardiography (ECG), skin temperature, and body position during the study period.
Measurements obtained from the investigational device will be compared with simultaneous standard-of-care bedside monitoring and capnography for validation purposes.
|
|
Infants
Hospitalized infants aged 29 days to <2 years admitted to the NICU or PICU
|
Participants will wear the ANNE® Chest wireless skin-adherent physiologic sensor for continuous monitoring of heart rate, respiratory rate, electrocardiography (ECG), skin temperature, and body position during the study period.
Measurements obtained from the investigational device will be compared with simultaneous standard-of-care bedside monitoring and capnography for validation purposes.
|
|
Children
Hospitalized children aged 2 to <12 years admitted to the PICU
|
Participants will wear the ANNE® Chest wireless skin-adherent physiologic sensor for continuous monitoring of heart rate, respiratory rate, electrocardiography (ECG), skin temperature, and body position during the study period.
Measurements obtained from the investigational device will be compared with simultaneous standard-of-care bedside monitoring and capnography for validation purposes.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Respiratory Rate Accuracy
Tidsram: Study monitoring period (4 to 8 hours per day over 2 consecutive days)
|
Agreement between respiratory rate measured by the ANNE® Chest wireless sensor and the reference standard capnography.
Accuracy will be evaluated using agreement analyses, with success defined as wearable-derived respiratory rate values within ±3 breaths per minute of the reference standard.
|
Study monitoring period (4 to 8 hours per day over 2 consecutive days)
|
|
Heart Rate Accuracy
Tidsram: Study monitoring period (4 to 8 hours per day over 2 consecutive days)
|
Agreement between heart rate measured by the ANNE® Chest wireless sensor and the reference standard bedside monitor.
Accuracy will be evaluated using agreement analyses, with success defined as wearable-derived heart rate values within ±5 beats per minute of the reference monitor.
|
Study monitoring period (4 to 8 hours per day over 2 consecutive days)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Skin Tolerability
Tidsram: Baseline (prior to device placement), immediately after device removal, and approximately 30 minutes after device removal.
|
Skin tolerability of the ANNE® Chest sensor, including the presence of erythema, irritation, or pressure marks following device use.
Skin integrity will be assess by comparing before and after photos of sites of placement of wearable sensors using the Berger & Bowman Scoring Scale.
|
Baseline (prior to device placement), immediately after device removal, and approximately 30 minutes after device removal.
|
|
Caregiver and Healthcare Provider Device Usability Perspective
Tidsram: Immediately following completion of study participation.
|
Caregiver and healthcare provider feedback regarding the usability and acceptability of the ANNE®.
Parent and clinician perceptions will be assessed using a custom study questionnaire containing Likert-scale, multiple-choice, and open-ended questions addressing usability, comfort, perceived safety, perceived accuracy, and overall acceptability of the wireless monitoring system.
|
Immediately following completion of study participation.
|
|
Respiratory Rate Average Root Mean Squared Error (ARMS)
Tidsram: Study monitoring period (4 to 8 hours per day over 2 consecutive days)
|
Average Root Mean Squared Error (ARMS) between respiratory rate measurements obtained from the ANNE® Chest sensor and the reference monitor within each age cohort.
|
Study monitoring period (4 to 8 hours per day over 2 consecutive days)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Guilherme Sant'Anna, MD, PhD, RI-MUHC
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 september 2026
Primärt slutförande (Beräknad)
1 september 2027
Avslutad studie (Beräknad)
1 september 2027
Studieregistreringsdatum
Först inskickad
28 juli 2026
Först inskickad som uppfyllde QC-kriterierna
28 juli 2026
Första postat (Faktisk)
31 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
31 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
28 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- Wireless PICU
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Ja
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .